Charles River Labs Intl Stock
Price
Target price
€179.50
€179.50
0.080%
0.15
0.080%
€247.61
09:30 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
There is nearly no change for the Charles River Labs Intl stock today. Compared to yesterday it only changed by €0.15.
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Charles River Labs Intl.
As a result the target price of 247 € shows a positive potential of 37.6% compared to the current price of 179.5 € for Charles River Labs Intl.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | 0.080% | 2.063% | -4.616% | -9.946% | -17.535% | -53.035% | - |
| Ironwood Pharmaceuticals | 1.490% | 0.000% | 5.128% | -47.436% | -59.804% | -59.406% | -51.872% |
| Arrowhead Pharmaceuticals Inc. | 3.940% | -3.265% | -5.984% | -28.448% | -31.090% | -63.891% | -28.645% |
| Novocure Ltd | -0.160% | 3.881% | -9.138% | -13.481% | 9.702% | -85.419% | -78.116% |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at UBS Group AG from $290.00 to $240.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Evercore ISI from $265.00 to $225.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target lowered by analysts at Robert W. Baird from $271.00 to $239.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
Charles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:
-
Morgan Stanley 22nd Annual Global Healthcare
Charles River Laboratories Announces Second-Quarter 2024 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06